Nilotinib and Imatinib Utilization in Iran over 14 years

Nilotinib and Imatinib Utilization in Iran over 14 years

Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML) treatment. CML healthcare costs greatly exceed of other haematological malignancies treatment mostly due to TKIs. There are several generic and brand preparations of imatinib and nilotinib, the only...

Full description

Bibliographic Details
Main Authors: Ava Mansouri, Kimia Hirbod, Maryam Taghizadeh-Ghehi, Aarefeh Jafarzadeh Kohneloo, Mohammad Solduzian, Molouk Hadjibabaie
Format: Article
Language:English
Published: Research Center for Rational Use of Drugs (RCRUD) 2020-12-01
Series:Journal of Pharmaceutical Care
Subjects:
Nilotinib
Imatinib
Chronic Myeloid Leukemia
Insurance Coverage
Drug Prescriptions
Drug Utilization Review
Online Access:https://jpc.tums.ac.ir/index.php/jpc/article/view/378

Internet

https://jpc.tums.ac.ir/index.php/jpc/article/view/378

Similar Items